Comparison of 18F-DCFPyL and 68Ga-PSMA-11 for 177Lu-PSMA-617 therapy patient selection.

Purpose: ⁶⁸Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for ¹⁷⁷Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with ⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPyL. Methods: We retrospectively evaluated 80 patients undergoing PSMA RLT, who had pretreatment imaging using either ⁶⁸Ga-PSMA-11 or ¹⁸F-DCFPyL. For both groups, we compared the biodistribution and lesion uptake and the PSA response to treatment. Results: Both agents had comparable biodistribution. Patients initially imaged with ¹⁸F-DCFPyL had a higher PSA response (66% vs. 42%), and more patients had a PSA50 response (72% vs. 43%) compared to patients imaged with ⁶⁸Ga-PSMA-11. Conclusion: ¹⁸F-DCFPyL and ⁶⁸Ga-PSMA-11 had comparable biodistribution and lesion uptake. Patients imaged with ¹⁸F-DCFPyL demonstrated clinical benefit to PSMA RLT comparable to those imaged with ⁶⁸Ga-PSMA-11, and either agent can be used for screening patients. [ABSTRACT FROM AUTHOR]